Ezentimibe Tablets 10 mg (Ezetimibe)
Ezetimibe 10mg
Tablet · Prescription medication
YuYu Pharmaceutical Co., Ltd.
MFDS item code 201902131 · Approved 2019.04.08
This product's status changed to Expired on 2024.04.08. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of hypercholesterolemia, mixed hyperlipidemia, and sitosterolemia
This medication is used to treat various types of hyperlipidemia, including primary hypercholesterolemia, homozygous familial hypercholesterolemia, and homozygous sitosterolemia. It helps effectively reduce total cholesterol, low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B. Additionally, in patients with mixed hyperlipidemia, it may be co-administered with fenofibrate to help lower non-high-density lipoprotein cholesterol (non-HDL-C). This medication is used in conjunction with dietary management and can be combined with statins or other lipid-lowering therapies to enhance therapeutic effects if needed. In complex cases of hyperlipidemia, secondary causes should be identified and treated before using this medication. Therefore, this drug is effective in improving cholesterol levels and is used to reduce the risk of cardiovascular diseases.
Continue a standard cholesterol-lowering diet during treatment with this medicine. The recommended dose of this medicine is 10 mg once daily, regardless of meals. When administered in combination with an HMG-CoA reductase inhibitor (in patients with primary hypercholesterolemia), start this medicine in combination with the recommended initial dose of the HMG-CoA reductase inhibitor. If the patient is already receiving a high dose of an HMG-CoA reductase inhibitor, administer this medicine concomitantly while maintaining the dose of the HMG-CoA reductase inhibitor. When this medicine is administered in combination with fenofibrate (in patients with mixed hyperlipidemia), administer it with fenofibrate 160mg once daily or 200mg once daily (see Precautions for Use 4. General Precautions). Administration to patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment; however, use of this medicine is not recommended in patients with moderate to severe hepatic impairment (see Precautions for Use 2. Patients Requiring Caution). Administration to patients with renal impairment No dose adjustment is required in patients with renal impairment. Administration to elderly patients No dose adjustment is required when administering this medicine to elderly patients. Concomitant administration with bile acid sequestrants Administer this medicine at least 2 hours before or 4 hours after administration of a bile acid sequestrant (see Precautions for Use 5. Interactions).
This medication should not be used in patients who have hypersensitivity to any of its ingredients. Patients with active liver disease or persistent liver function abnormalities should be cautious as co-administration with certain lipid-lowering agents may worsen liver damage. Women who are pregnant or breastfeeding are prohibited from using this medication with certain lipid-lowering agents, and women who may become pregnant should consult a doctor. This medication is not recommended for patients with moderate to severe liver dysfunction. While generally safe, side effects such as headache, abdominal pain, diarrhea, fatigue, and myalgia may occur. If symptoms such as myalgia or muscle weakness occur, promptly inform healthcare personnel, and in severe cases, discontinuation of the medication may be required. Patients with severely impaired kidney function do not require dosage adjustment; however, those with reduced kidney function should be monitored closely. This medication may interact with other lipid-lowering agents or specific anticoagulants, so patients should inform healthcare personnel of any other medications they are taking. During pregnancy or breastfeeding, the potential risks and benefits of this medication should be carefully considered. Its use is not recommended in children under 6 years old, and it should be administered to children and adolescents over 6 years at the discretion of a physician. It may also be used in elderly patients, but caution is necessary as some may be more sensitive to the medication. In cases of overdose, seek immediate medical attention for appropriate treatment. This medication should be stored out of reach of children, and it is advised not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air or moisture, and the temperature should be maintained between 1°C and 30°C at room temperature. Proper storage helps maintain the medication's effectiveness and prevents degradation.
White to off-white rectangular tablet
10 tablets/PTP, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ezetimibe 10mg
Tablet · Prescription medication
YuYu Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Korea Organon Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Hanmi Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Genewon Science Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Shin Il Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Korea Hutech Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Hwanin Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Jinyang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.